Sorry, this entry is only available in Norwegian Bokmål.
Author: Ola Myklebost
Vokste opp på Eiksmarka og Haslum i Bærum, bodde 30 år på Trollåsen i Oppegård, bor nå på Nordnes i Bergen
Korrespondanse om bioteknologiloven og forskning
Publications 2018
Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O,Knappskog S, Lønning PE (2018) Patterns of genomic evolution in advanced melanoma. Nature Comm DOI: 10.1038/s41467-018-05063-1
Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E (2018) Preclinical evaluation of vemurafenib as therapy for BRAFV600E mutated sarcomas Int J Mol Sci DOI:10.3390/ijms19040969
Kresse SK, Namløs HM, Lorenz S, Berner JM, Ola Myklebost O, Bjerkehagen B, Meza-Zepeda LA(2018) Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples. PLoS One https://doi.org/10.1371/journal.pone.0197456
Nakken S, Fournous G, Vodak D, Aasheim B, Myklebost O, Hovig E (2017) Personal Cancer Genome Reporter: Variant Interpretation Report For Precision Oncology. Bioinformatics 1–3 doi:10.1093/bioinformatics/btx817
Namløs H, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA(2018) Non-invasive detection of ctDNA reveals intratumour heterogeneity and is significantly associated with aggressive GIST Mol Cancer Ther 10.1158/1535-7163.MCT-18-0174
Serguienko A, Wang MY, Myklebost O(2018) Real-time vital mineralization detection and quantification during in vitro osteoblast differentiation. Biological Procedures Online (2018) 20:14 DOI: 10.1186/s12575-018-0079-4
Strauss SJ, Anninga J, Baglio B, Baumhoer D, Behjati S, Bielack S, Boye K, Broto JM, Cleton‑Jansen AM, Degasperi A, Evans A, Fagioli F, Fiocco M, Gaspar N, Heymann D, Hindi N, Lancia C, Myklebost O, Nathrath M, Redini F, Scotlandi K, Tirtei E, Vanden Eynden M, Whelan J (2018) Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma Clin Sarcoma Res 8:17 DOI:10.1186/s13569-018-0103-0
Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018) Sample-Index Misassignment Impacts Tumour Exome Sequencing Sci. Rep. DOI:10.1038/s41598-018-23563-4
Repurposing drugs for sarcoma patients
Like so many orphan, or neglected, cancers, therapies for sarcomas have, with a few exceptions, not improved much the last decades. Surgery, radiation and chemotherapy are the main treatment arms, but chemotherapy appears to have reached a limit due to high toxicities, and has not significantly improved this century. A notable exception is the treatment of GIST with drugs targeting the c-kit pathway, which is a prime example of successful repurposing of a drug. Imatinib was developed to target the fusion protein bcr-abl which causes leukemia, but turned out to also be very effective against the mutated kit receptor in GIST (gastrointestinal stromal tumours). We are trying to identify other such drugs, developed and perhaps approved for another cancer type, but having activity against sarcomas.
Candidate sarcoma drugs are identified by two main projects: Determining cancer mechanisms that are mutated in sarcomas, or drug screening of drug libraries on sarcoma cells in culture. In the first project we identify mutated mechanisms that have been exploited in therapies in other cancers. However, although we may find the same mutations that predict response in another cancer, this may not be the case in sarcomas. We therefore have to find one or more cell lines with this type of mutation, and test their sensitivity to the drug. If it works it is promising, but we still do not know if it will work in a patient, as there are so many differences between a cell culture and a body. Some of these issues may be accounted for by investigating the activity in a human sarcoma grown in mice, but still this is just a first stepping-stone for clinical trials, there are many differences between such an artificial experimental system and real tumours in patients.
To determine the efficacy in patients, a clinical trial has to be organised and funded.
NoSarC, – A national, prospective sarcoma study
NoSarC, – the NOrwegian SArcoma Consortium, is a collaboration between sarcoma scientists and clinics in all Norwegian health regions to collect and analyse samples form (almost) all sarcoma patients over 3 years. Depending on funding, we are determining all mutations in the tumours by “next generation sequencing” samples from tumours and blood in all cases where tumour is available.
Publications 2017
Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O, Bjerkehagen B, Myklebost O, Amary MF, Tirabosco R, Van Loo P, Stratton MR, Flanagan AM, Campbell PJ (2017) Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma Nature Communications 23:15936 doi: 10.1038/ncomms15936
Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017) Multi-omics of 34 colorectal cancer cell lines – a resource for biomedical studies Mol Cancer 16:116 doi: 10.1186/s12943-017-0691-y
Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Munthe E, Myklebost O (2017) Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b Sci Rep DOI:10.1038/s41598-017-10189-1
Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017) High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival. Int J Cancer 141:184-190 doi: 10.1002/ijc.30726
Nakken S, Fournous G, Vodak D, Aasheim B, Myklebost O, Hovig E (2017) Personal Cancer Genome Reporter: Variant Interpretation Report For Precision Oncology. Bioinformatics 1–3 doi:10.1093/bioinformatics/btx817
Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017) Monitoring of Multiple Myeloma by quantification of recurrent mutations in serum Haematologica 102:1266-1272 doi: 10.3324/haematol.2016.160564
Serguienko A, Hanes R,Grad I, Wang MY, Munthe E, Myklebost O (2017) PP2A regulatory subunit B55γ is a gatekeeper of osteoblast maturation and lineage maintenance Stem Cells Devel 26: 1375-1383 doi: 10.1089/scd.2017.0129
Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017) Multilevel genomics of colorectal cancers with microsatellite instability – clinical impact of JAK1 mutations and consensus molecular subtype 1 Genome Medicine 9:46 doi: 10.1186/s13073-017-0434-0
Publications 2016
Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall L, Judson I, Seddon B, Cambell IG, Young MA, Sarin R, Blay JY, O’Donoghue SI, Thomas D (2016) Novel monogenic and polygenic determinants of sarcoma risk: an international study of 1162 families Lancet Oncology 17:1261–1271 PDF
- Editorial Comment: Are sarcomas hereditary?
- Editorial comment in Cancer Discovery: Unfurling the Genetic Map of Sarcomas
Barøy T, Chilamakuri CSR, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA (2016) Genome analysis of osteosarcoma progression samples identifies FGFR1 overexpression as a potential treatment target and CHM as a candidate tumor suppressor gene Plos One 11: e0163859 DOI:10.1371/journal.pone.0163859
Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O; Børresen-Dale AL, Brustugun OT, Helland Å (2016) TP53 mutation spectrum in smokers and never smoking lung cancer patients Frontiers in Genetics 7:85.
Hanes, R., I. Grad, S. Lorenz, E. W. Stratford, E. Munthe, C. C. S. Reddy, L. A. Meza-Zepeda and O. Myklebost(2016). Amplified FRS2 identified as a target for treatment of dedifferentiated liposarcoma by genome sequencing and functional validation. Oncotarget 7:54583.
Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JV, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GH, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS (2016) The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. Clin Sarcoma Res. 16;6:3
Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2016) Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report BMC Cancer In press
Sandhu V, Wedge DC, Lothe IMB, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børressen-Dale AL, Ikdahl T, Van Loo P, Nord S (2016) The genomic landscape of pancreatic and periampullary adenocarcinoma. Cancer Research 76(17); 1–11
Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T (2016)
VOLIN and KJON-Two novel hyperdiploid myeloma cell lines Genes Chromosomes Cancer, 55 (11), 890-901
PubMed 27311012
Publications 2015
Budin-Ljøsne I, Bentzen HB, Solbakk JH, Myklebost O (2015) Genome sequencing in research requires a new approach to consent Tidskr Nor Legeforening PDF
Chymkowitch P, Nguéa P A, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM (2015) Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes Genome Res, 25 (6), 897-906 PubMed 25800674
Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015) Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol, 16, 7 PubMed 25650807
Ju YS, Tubio JMC, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A,Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Ta M, Lee M, van’t Veer LJ, Tan BKT, Aparicio S, Span PN, Martens JWM, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PM, Stratton MR (2015) Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells Genome Res 25:814-24. doi: 10.1101/gr.190470.115
Kanojia D, Nagata Y, Garg M, Lee DH, Anand MT, Christoph H, Klein HU, Said JW, Doan NB, Mohith S, Gunasekar S, Myklebost O, Yang H, Dugas M, Meza‐Zepeda LA, Silberman AW, Forscher C, Ogawa S, Koeffler HP (2015) Genomic landscape of liposarcoma Oncotarget DOI: 10.18632/oncotarget.6464
Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GOS, Skotheim RI, Lothe RA, Tarpey P, Campbell P, Flanagan A, Meza-Zepeda LA, Myklebost O (2015) Unscrambling the genomic chaos of osteosarcoma reveals recurrent rearrangements and frequent novel TP53 aberrations Oncotarget DOI: 10.18632/oncotarget.6567
Myklebost O (2015) Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls (Review) Personalized Medicine 12:593-602 PDF
Myklebost O (2015) Norwegian Cancer Genomics Consortium, a platform for research on personalized cancer medicine in a public health system. Drug Discovery Today: Special issue on Stratified Medicine doi:10.1016/j.drudis.2015.10.003
Naderi EH, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ellen Ruud E, Naderi S, Blomhoff HK (2015) Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death, Mol Cancer in press doi:10.1186/s12943-014-0278-9
Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost, Ola, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E,Sandvik A, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015) Clinical and biological implications of BRAF V600E mutation in multiple myeloma. Blood Cancer J doi: 10.1038/bcj.2015.24
Safavi S, Järnum S, Vannas C, Udane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stock ES, Ståhlberg A, Åman P (2015) HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget PDF
Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Ola Myklebost O, Munthe E (2015) Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA Oncotarget 6(4): 2451–2465
Publications 2014
Anninga JK, Cleton-Jansen AM, Hassan B, Amary MF, Baumhoer D, Blay JY, Brugieres L, Ferrari S, Jürgens H, Kempf-Bielack B, Kovar H, Myklebost O, Nathrath M, Picci P, Riegman P, Schilham MW, Soliman R, Stark DP, Strauss A, Sydes M, Tarpey P, Thomas D, Whelan J, Wilhelm M, Zamzam M, Gelderblom H, Bielack SS (2014) Workshop Report on the 2nd Joint ENCCA/EuroSARC European Bone Sarcoma Network Meeting: Integration of Clinical Trials with Tumour Biology. Clinical Sarcoma Research 4:4 PDF
Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA (2014) Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model. Molecular Cancer 13:93 doi:10.1186/1476-4598-13-93 PDF
Chilamakuri CSR, Lorenz S, Madoui MA, Vodák DA, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA (2014) Performance Comparison of four exome capturing systems for deep sequencing. BMC Genomics PDF
Garsed DW, Marshall OJ, Corbin VDA, Hsu A, di Stefano L, Schröder J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda LA, Holloway AJ, Pedeutour F, Choo KHA, Damore MA, Deans AJ, Papenfuss AT, Thomas DM (2014) Architecture and Evolution of a Cancer Neochromosome, Cancer Cell 26:653-667 PDF
- Comment in Cancer Cell by Waterfall and Meltzer PDF
Håkelien AM, Bryne JC, Harstad KG, Lorenz S, Paulsen J, Sun J, Mikkelsen TS, Myklebost O, Meza Zepeda LA(2014) The regulatory landscape of osteogenic differentiation. Stem Cells PDF
- Awarded as one of the best OUS papers 2014
Skårn M, Noordhuis P, Wang MY, Veuger MJT, Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O (2014) Generation and characterisation of an immortalised human bone marrow derived mesenchymal stromal cell line. Stem Cells and Development PDF
These cells are now available commercially from Applied Biological Materials Inc
Stratford EW, Myklebost O (2014) TRAP1 is a novel interaction partner of PML, localised with PML in nuclear bodies and relocating with PML to the cytoplasm following stress. Annual research and review in biology 3:36-46 PDF
Tran D, Verma K, Ward K, Diaz D, Kataria E, Torabi A, Almeida A, Malfoy B, Stratford EW, Mitchell DC, Bryan BA (2014) Functional Genomics Analysis Reveals a MYC Signature Associated with a Poor Clinical Prognosis in Liposarcomas Am J Pathol In press doi:10.1016/j.ajpath.2014.11.024
Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O’Meara S, Andreson E, Maddison M, Gamble S, ICGC Breast Cancer Group, ICGC Bone Cancer Group, ICGC Prostate Cancer Group, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, van’t Veer L, Caldas C, Desmedt C, Sotiriou C, Aparicio A, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL,van de Vijver M, Vincent-Salomon A, van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ (2014) Extensive transduction of non-repetitive DNA mediated by L1 retrotransposition in cancer genomes Science 345 no. 6196 DOI: 10.1126/science.1251343
Wennerström AB, Lothe IMB, Sandhu V, Kure E, Myklebost O, Munthe E (2014) Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines. PLoS One 10.1371/journal.pone.0103873
Publications 2013
Behjati S, Tarpey PS, Presneau N, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gudem G, Davies H, Nik-Zainal S, Gamble J, Hardy C, Latimer C, Maddison M, Martin S, McLaren S, Mudie L, O’Meara S, Robinson B, Butler A, Teague JW, Kathri B, Halai D, Myklebost O, Baumhoer D, Jundt G, Tirabosco R, Amary F, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM (2013) Distinct H3F3A and H3F3B driver variants define chondroblastoma and giant cell tumour of bone Nat Genet45:1479-82. doi: 10.1038/ng.2814
Bianchini L, Birtwisle L, Saâda E, Bazin A, Long E, Roussel JF, Michiels JF, Forest F, Dani C, Myklebost O, Birtwisle-Peyrottes I, Pedeutour F. (2013) Identification of PPAP2B as a novel recurrent translocation partner gene of HMGA2 in lipomas. Genes Chromosomes Cancer doi: 10.1002/gcc.22055 PDF
Doorn J, Hugo Fernandes H, Lee B, van de Peppel J, van Leeuwen JPTM, De Vries MR, Aref Z, Quax PHA, Myklebost O, Saris D, van Blitterswijk CA, de Boer J. (2013) A small molecule approach to engineering vascularized tissue. Biomaterials 34 (12), 3053-63 PDF
Kuijjer ML, Peterse EFP, van den Akker BEWM, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PCW, Cleton-Jansen AM (2013) IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma BMC Cancer 13:245 doi:10.1186/1471-2407-13-245
Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA Myklebost O (2013) Functional characterization of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes Br. J. Cancer in press PDF
Nome T, Thomassen GOS, Bakken AC, Bruun J, Ahlquist T, Lorenz S, Sun J, Barros-Silva JD, Myklebost O, Teixeira M, Meza-Zepeda LA, Lothe RA, Skotheim RI (2013) Common fusion transcripts identified in colorectal cancer cell lines by high throughput RNA sequencing. Translational Oncology 6:546–553 PDF
Qu S, Olafsrud SM, Meza-Zepeda LA, Saatcioglu F (2013) Rapid gene expression changes in peripheral blood lymphocytes upon practice of a comprehensive yoga program PLoS One, 8 (4), e61910
Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W, Langmoen IA (2013) Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome Experimental Cell Research, PDF
Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K (2013) Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer PLoS One, 8 (6), e66165
Stratford EW, Bostad M, Castro R, Skarpend E, Berg K, Høgset A, Myklebost O, Selbo PK (2013) Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity Biochim Biophys Acta 1830:4235-43. doi: 10.1016/j.bbagen.2013.04.033s
Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, Krauss S, Myklebost O (2013) The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Medicine doi:10.1002/cam4.170
Skårn M, Barøy T, Stratford EW, Myklebost O (2013) Epigenetic regulation and functional characterization of mir-142 in mesenchymal cells PLoS One Link
Thomas D, Myklebost O, Meza-Zepeda LA (2013) Research in Well-Differentiated and Dedifferentiated Liposarcoma ESUN – A Periodical for the Sarcoma Community, Volume 10, Number 1 Link
Wang P, Gao1 Q, Suo Z, Munthe E, Solberg S, Ma L, Wang MY, Westerdaal NAC, Kvalheim G, Gaudernack G (2013) Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines PLoS One in press